Bajaj Healthcare Limited has successfully completed the allotment of 20,79,409 equity shares following the conversion of convertible warrants by 8 investors. The board meeting held on March 18, 2026, approved the allotment at an issue price of ₹338 per share, including a premium of ₹333 per share.

Board Meeting Outcome

The board of directors, in their meeting held on March 18, 2026, considered and approved the allotment of fully paid-up equity shares to promoter, promoter group, and non-promoter public category investors. The meeting commenced at 4:33 PM and concluded at 5:05 PM, with the outcome communicated to both BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI LODR Regulations.

Investor-wise Allotment Details

The warrant conversion involved 8 investors across different categories, with Swastik Capital being the largest beneficiary. All warrant holders exercised their conversion option and paid the balance 75% consideration amount.

Capital Structure Impact

Following the allotment, the company's issued, subscribed and paid-up equity share capital has increased significantly. The newly allotted equity shares rank pari-passu with existing shares in all respects, including dividend rights.

Regulatory Compliance

The allotment was conducted in accordance with the special resolution passed by shareholders at the Extra-Ordinary General Meeting held on August 07, 2024, and complies with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The original warrants were allotted on September 19, 2024, with an 18-month conversion period. With this allotment, no warrants remain outstanding for conversion.

Bajaj Healthcare Limited has announced the sale of its undertaking to Bethany Pharmacare Private Limited through a regulatory disclosure filed on March 17, 2026. The transaction involves the disposal of the company's facility located at Plot No. L-9/3, MIDC, Tarapur, Taluka Boisar, District Palghar, Maharashtra.

Transaction Details

The company has signed a Deed of Assignment and Transfer with Bethany Pharmacare Private Limited for the sale of the undertaking. The key parameters of this transaction are outlined below:

Operational and Financial Impact

The undertaking being sold was not operational during the last financial year, resulting in nil contribution to the company's turnover or revenue. This indicates that the disposal involves a non-productive asset that was not generating income for Bajaj Healthcare Limited.

The transaction is expected to be completed upon fulfillment of conditions mentioned in the Deed of Assignment and Transfer, though no specific completion timeline has been disclosed.

Regulatory Compliance

Bajaj Healthcare Limited has confirmed several important aspects regarding the transaction's compliance:

Prior Approvals and Governance

The company had proactively obtained shareholder approval for this disposal through a postal ballot process. The approval was secured on August 05, 2023, via postal ballot notice dated June 28, 2023. This demonstrates the company's adherence to proper governance procedures and compliance with SEBI LODR Regulation 37A requirements.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders regarding this material corporate action.